Research

Approved MBC Drugs + Dosages

Dosage-Related Studies

Correlation Between Low BMI and Neutropenia Risk on Ibrance

Articles by Patients

Komen Blog by Sandi Spivey: Let’s say you are a patient with MBC and you’ve been on a few lines of therapy. You have progression and Drug X is your next option. Even if you have low blood counts, have experienced eventual stepdown doses on your other therapies due to sensitivities or side effects, you are to start at the MTD. Why? Because that’s what the guidelines say. Does this sound right to you?" https://blog.komen.org/blog/the-right-dose/

When the ‘Maximum Tolerable Dose’ of Cancer Treatment Isn’t Tolerable" by Martha Carlson in Cure Today Magazine: "Who doesn’t want to reduce toxicity and maintain clinical effectiveness? In fact, cancer drug development in current clinical trial protocols does not seek to do that." https://www.curetoday.com/view/when-the-maximum-tolerable-dose-of-cancer-treatment-isn-t-tolerable